LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・IQVIA Holdings Inc

IQVIA Holdings Inc

Gesloten

SectorGezondheidszorg

168.23 0.25

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

167.51

Max

169.05

Belangrijke statistieken
By Trading Economics
Inkomsten	-239M 275M
Verkoop	-213M 4.2B
K/W Sectorgemiddelde	21.576 49.701
EPS	2.9
Winstmarge	6.625
Werknemers	93,000
EBITDA	-245M 802M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+28.65% upside

Dividenden
By Dow Jones
Volgende Winsten	21 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	2B 29B
Vorige openingsprijs	167.98
Vorige sluitingsprijs	168.23

Nieuwssentiment

By Acuity

23%

77%

41 / 345 Rangschikking in Healthcare

IQVIA Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 mei 2026, 08:24 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mei 2026, 21:22 UTC

Winsten

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mei 2026, 20:50 UTC

Marktinformatie

Winsten

Basic Materials Roundup: Market Talk

25 mei 2026, 16:20 UTC

Marktinformatie

Winsten

Basic Materials Roundup: Market Talk

25 mei 2026, 16:01 UTC

Marktinformatie

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mei 2026, 14:43 UTC

Marktinformatie

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mei 2026, 14:15 UTC

Marktinformatie

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mei 2026, 13:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

25 mei 2026, 12:58 UTC

Marktinformatie

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mei 2026, 12:56 UTC

Marktinformatie

Winsten

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mei 2026, 12:48 UTC

Marktinformatie

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mei 2026, 12:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

25 mei 2026, 12:34 UTC

Marktinformatie

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mei 2026, 12:10 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Delivery Hero's Assets Look Strategic -- Market Talk

25 mei 2026, 11:00 UTC

Marktinformatie

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mei 2026, 10:19 UTC

Marktinformatie

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mei 2026, 10:05 UTC

Winsten

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mei 2026, 10:04 UTC

Winsten

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mei 2026, 10:03 UTC

Winsten

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mei 2026, 10:02 UTC

Winsten

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mei 2026, 10:01 UTC

Winsten

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mei 2026, 10:00 UTC

Winsten

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q EPS MYR0.1883

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q Rev MYR17.1B

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q Net MYR1.1B

25 mei 2026, 09:38 UTC

Marktinformatie

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mei 2026, 09:33 UTC

Marktinformatie

Global Equities Roundup: Market Talk

25 mei 2026, 09:33 UTC

Marktinformatie

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mei 2026, 08:55 UTC

Marktinformatie

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer Vergelijking

Prijswijziging

IQVIA Holdings Inc Prognose

Koersdoel

By TipRanks

28.65% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 216 USD 28.65%

Hoogste 245 USD

Laagste 185 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor IQVIA Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan IQVIA Holdings Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

41 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.